29 citations as recorded by crossref.

1. Prosthetic Knee Infection With Coagulase-Negative Staphylococcus: A Harbinger of Poor Outcomes L. Charalambous et al. 10.1016/j.arth.2022.02.050
2. Risk Factors of DAIR Failure and Validation of the KLIC Score: A Multicenter Study of Four Hundred Fifty-Five Patients M. Bernaus et al. 10.1089/sur.2021.320
3. Efficacy and safety of colistin plus beta-lactams for bone and joint infection caused by fluoroquinolone-resistant gram-negative bacilli: a prospective multicenter study M. Mancheño-Losa et al. 10.1007/s15010-024-02379-7
4. Delayed Rifampin Administration in the Antibiotic Treatment of Periprosthetic Joint Infections Significantly Reduces the Emergence of Rifampin Resistance A. Darwich et al. 10.3390/antibiotics10091139
5. Clinical outcome of postoperative surgical site infections in patients with posterior thoracolumbar and lumbar instrumentation T. Zhang et al. 10.1016/j.jhin.2022.06.014
6. Truth in DAIR: Duration of Therapy and the Use of Quinolone/Rifampin-Based Regimens After Debridement and Implant Retention for Periprosthetic Joint Infections D. Tai et al. 10.1093/ofid/ofac363
7. Incidence of Rifampicin Resistance in Periprosthetic Joint Infection: A Single-Centre Cohort Study on 238 Patients S. Lazarinis et al. 10.3390/antibiotics12101499
8. Material-based treatment strategies against intraosseous implant biofilm infection Z. Pan et al. 10.1016/j.bbrep.2024.101764
9. CORR Insights®: Lower Success Rate of Débridement and Implant Retention in Late Acute versus Early Acute Periprosthetic Joint Infection Caused by Staphylococcus spp. Results from a Matched Cohort Study J. Drew 10.1097/CORR.0000000000001283
10. Rifampin-resistant periprosthetic joint infections are associated with worse functional outcome in both acute and chronic infection types T. Baumgärtner et al. 10.1016/j.diagmicrobio.2024.116447
11. If, When, and How to Use Rifampin in Acute Staphylococcal Periprosthetic Joint Infections, a Multicentre Observational Study M. Beldman et al. 10.1093/cid/ciab426
12. Rifampin, Rifapentine, and Rifabutin Are Active against Intracellular Periprosthetic Joint Infection-Associated Staphylococcus epidermidis C. Fisher & R. Patel 10.1128/AAC.01275-20
13. Quality of life, infection control, and complication rates using a novel custom-made articulating hip spacer during two-stage revision for periprosthetic joint infection A. Lunz et al. 10.1007/s00402-021-04274-4
14. Should We Use Rifampicin in Periprosthetic Joint Infections Caused by Staphylococci When the Implant Has Been Exchanged? A Multicenter Observational Cohort Study T. Kramer et al. 10.1093/ofid/ofad491
15. Rifampin in device-related infections: Assessing the modern evidence S. Durham et al. 10.1093/ajhp/zxae263
16. How We Approach Suppressive Antibiotic Therapy Following Debridement, Antibiotics, and Implant Retention for Prosthetic Joint Infection N. Cortes-Penfield et al. 10.1093/cid/ciad484
17. Bone mineral as a drug-seeking moiety and a waste dump D. Raina et al. 10.1302/2046-3758.910.BJR-2020-0097.R1
18. Clinical outcomes of rifampicin combination therapy in implant-associated infections due to staphylococci and streptococci: A systematic review and meta-analysis E. Yusuf et al. 10.1016/j.ijantimicag.2023.107015
19. Reply to Scheper and de Boer's comment on “Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to Staphylococcus treated with a debridement, antibiotics and implant retention (DAIR): a retrospective multicenter study in France” by Becker et al. (2020) A. Becker et al. 10.5194/jbji-6-19-2020
20. Outcome of Debridement, Antibiotics, and Implant Retention for Staphylococcal Hip and Knee Prosthetic Joint Infections, Focused on Rifampicin Use: A Systematic Review and Meta-Analysis H. Scheper et al. 10.1093/ofid/ofab298
21. Extended local release and improved bacterial eradication by adding rifampicin to a biphasic ceramic carrier containing gentamicin or vancomycin S. Sebastian et al. 10.1302/2046-3758.1111.BJR-2022-0101.R1
22. The Use of Rifampin in Total Joint Arthroplasty: A Systematic Review and Meta-Analysis of Comparative Studies C. Kruse et al. 10.1016/j.arth.2022.03.072
23. In vitroantibiotic activity against intraosteoblasticStaphylococcus aureus: a narrative review of the literature F. Marro et al. 10.1093/jac/dkab301
24. A review of current practices in periprosthetic joint infection debridement and revision arthroplasty H. Mian et al. 10.1186/s42836-022-00136-5
25. Effectiveness and Optimal Duration of Adjunctive Rifampin Treatment in the Management of Staphylococcus aureus Prosthetic Joint Infections After Debridement, Antibiotics, and Implant Retention H. Suzuki et al. 10.1093/ofid/ofac473
26. Rifampicin in periprosthetic joint infections: where do we stand and where are we headed? M. Wouthuyzen-Bakker & H. Scheper 10.1080/14787210.2023.2211263
27. Comment on “Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to Staphylococcus treated with a debridement, antibiotics and implant retention (DAIR): a retrospective multicenter study in France” by Becker et al. (2020) H. Scheper & M. de Boer 10.5194/jbji-6-17-2020
28. Effectiveness of rifampicin combination therapy for orthopaedic implant-related infections: A systematic review and meta-analysis N. Kobayashi et al. 10.1016/j.ijantimicag.2024.107359
29. Irrigation and Debridement With Chronic Antibiotic Suppression for the Management of Acutely Infected Aseptic Revision Total Joint Arthroplasties H. Salmons et al. 10.1016/j.arth.2023.05.092